Clayton Rabideau
Clayton is the founder of Syntensor, a startup that develops frontier models for drug development and human genetics with a particular focus on predicting the underlying drivers of clinical trial outcomes and trait prediction from human genomes.
â€
Syntensor Incorporated
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
-
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
AI-Driven Insights: Predicting Efficacy and Toxicity in Next-Gen Drug Discovery
-
AI is revolutionizing drug discovery—not just by accelerating timelines, but by enhancing our ability to predict how drugs behave in the body. This session highlights cutting-edge approaches like dynamic systems simulations that model mechanistic interactions at the cellular level. Learn how platforms are able to generating causal hypotheses to forecast both efficacy and toxicity, unlocking smarter, safer therapeutic development.